Felix Stehle

Dr. Felix Stehle

TU Dortmund University, 44227 Dortmund, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Biotechnology
Verified
Journal Article
Closed access
BZBastian Zirpel
Bastian Zirpel
OKOliver Kayser
Oliver Kayser
Felix StehleFelix Stehle
Felix Stehle

1 October 2017 in Journal of Biotechnology
Verified
Journal Article
Closed access
BZBastian Zirpel
Bastian Zirpel
FDFriederike Degenhardt
Friederike Degenhardt
CMChantale Martin
Chantale Martin
OKOliver Kayser
Oliver Kayser
Felix StehleFelix Stehle
Felix Stehle


17 June 2019 in Plant Biotechnology Journal
Verified
Journal Article
Open access
PDF file
JSJulia Schachtsiek
Julia Schachtsiek
Felix StehleFelix Stehle
Felix Stehle
Worldwide approximately 1.1 billion people are smokers and more than 7 million people die fromthe negative effects of smokingevery year(WHO report, 2017). One of the main natural ingredients causingdependence on tobacco is nicotine. Tobacco with a lowered nicotine content could help people to overcome their nicotine addiction. Nicotine‐free (or nicotine reduced) cigarettes may contribute to reduce the number of smokersand nicotine consumption, thus reducing the risk of death from tobacco use. Most genes involved in the nicotine biosynthesis in tobacco are known and well characterized (Dewey and Xie, 2013). This opens the possibility to employ genetic engineering approaches to alter the alkaloid content of the plant, and in particularto reduce the nicotine content. Nicotine itself is composed of a pyrrolidine and a pyridine ring, whichare synthesized in independent pathways (Figure 1 A). Recent approaches dealt with the silencing of upper pathway genes encoding the putrescine N‐methyltransferase (PMT) or A622, a phosphatidylinositol‐4‐phosphate (PIP)‐family member of NADPH‐reductases. The applied RNA silencing methods resulted either in the increased biosynthesisof other alkaloids like anatabine(i.e. Wang et al., 2009) or were only successful in hairy root cultures and BY‐2 cells, but not in whole plants(Kajikawa et al., 2009). The final oxidation step in the biosynthesis ofnicotine, as well as anatabine and anabasine, is proposed to be catalyzed by flavoproteins of the berberine bridge enzyme‐like (BBL) family(Kajikawa et al., 2011). The knockdown of the three most highly expressed BBL‐genes(BBLa–BBLc) by RNAi or the knockout with EMS‐induced mutations resulted in a reduction of the nicotine content without increasing the contentof other alkaloids(Kajikawa et al., 2011; Lewis et al., 2015). Recently, the BBL‐gene family in tobacco was expanded by the identification of BBLd.2 and BBLe,leading to six known isoforms(Kajikawa et al., 2017). Thus, the simultaneousknockout of theseBBL‐genes is a promising approach to generate a nicotine‐free tobacco plant.

1 June 2017 in FEMS Yeast Research
Verified
Journal Article
Open access
PDF file
ÂCÂngela Carvalho
Ângela Carvalho
EHEsben Halkjær Hansen
Esben Halkjær Hansen
OKOliver Kayser
Oliver Kayser
SCSimon Carlsen
Simon Carlsen
Felix StehleFelix Stehle
Felix Stehle
During the last decade, the use of medical Cannabis has expanded globally and legislation is getting more liberal in many countries, facilitating the research on cannabinoids. The unique interaction of cannabinoids with the human endocannabinoid system makes these compounds an interesting target to be studied as therapeutic agents for the treatment of several medical conditions. However, currently there are important limitations in the study, production and use of cannabinoids as pharmaceutical drugs. Besides the main constituent tetrahydrocannabinolic acid, the structurally related compound cannabidiol is of high interest as drug candidate. From the more than 100 known cannabinoids reported, most can only be extracted in very low amounts and their pharmacological profile has not been determined. Today, cannabinoids are isolated from the strictly regulated Cannabis plant, and the supply of compounds with sufficient quality is a major problem. Biotechnological production could be an attractive alternative mode of production. Herein, we explore the potential use of synthetic biology as an alternative strategy for synthesis of cannabinoids in heterologous hosts. We summarize the current knowledge surrounding cannabinoids biosynthesis and present a comprehensive description of the key steps of the genuine and artificial pathway, systems biotechnology needs and platform optimization.

1 January 2017
Verified
Book Chapter
Closed access
FDF. Degenhardt
F. Degenhardt
Felix StehleFelix Stehle
Felix Stehle
OKO. Kayser
O. Kayser